logo

For the Inventor, By the Inventor

Boulder, CO, United States of America

Array Biopharma Inc.


USPTO Granted Patents = 333

% Expired Patents = 30.3



Trademarks = 6

Forward Citations = 2,574

Loading Chart...
Loading Chart...

350 inventors (with patents filed for the assignee):

goldMedal James F Blake (106 out of 113 patents)

silverMedal Eli M Wallace (79 out of 91 patents)

bronzeMedal Joseph P Lyssikatos (66 out of 141 patents)

4.  Yutong Jiang (64 out of 68 patents)

5.  Steven Wade Andrews (64 out of 98 patents)

6.  Julia Haas (61 out of 64 patents)

7.  Gabrielle R Kolakowski (50 out of 58 patents)

8.  Qian Zhao (50 out of 65 patents)

9.  Shelley Allen (46 out of 48 patents)

10.  Mark Joseph Chicarelli (43 out of 47 patents)

11.  Tony P Tang (38 out of 44 patents)

12.  Adam Wade Cook (36 out of 41 patents)

13.  David A Moreno (35 out of 39 patents)

14.  Li Ren (32 out of 41 patents)

15.  Kevin Ronald Condroski (32 out of 42 patents)


Core Competencies:
Protein Kinase Inhibitors
KRas G12D
RET Kinase
FGFR Tyrosine Kinases
HER2 Inhibitors
Trk Kinase
BRAF
Pharmaceutical Compositions
Quinoxaline Compounds
Pyrazolo Compounds
Tyrosine Kinase
Combination Therapy

333 patents:

1. 12747253 - KRas G12D inhibitors (2026-09-29),
2. 12686692 - KRas G12D inhibitors (2026-07-21),
3. 12655160 - KRAS G12D inhibitors (2026-06-16),
4. 12630566 - KRas G12D inhibitors (2026-05-19),
5. 12465593 - Pharmaceutical composition (2025-11-11),
6. 12364684 - Pharmaceutical composition (2025-07-22),
7. 12351571 - Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases (2025-07-08),
8. 12318367 - Pharmaceutical composition (2025-06-03),
9. 12220403 - Pharmaceutical composition (2025-02-11),
10. 12187721 - Protein tyrosine phosphatase inhibitors (2025-01-07),
11. 12180207 - Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases (2024-12-31),
12. 12171739 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases (2024-12-24),
13. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),
14. 11964989 - KRas G12D inhibitors (2024-04-23),
15. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),
Company Overview
Array Biopharma Inc., based in Boulder, Colorado, specializes in the development of innovative therapies targeting cancer through protein kinase inhibitors. The company focuses on advancing treatments for various oncogenic mutations, including KRas G12D and BRAF, as well as targeting RET and FGFR tyrosine kinases. Array's expertise extends to HER2 and Trk kinase inhibitors, emphasizing the creation of effective pharmaceutical compositions aimed at improving patient outcomes in oncology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Array Biopharma Inc. USPTO Patent Assignee Logo
333 Patents

#3 in Boulder, CO

#28 in Colorado

#1,336 in US

#2,716 in the World

Boulder, CO (US)
Boulder, CO, United States of America

Array Biopharma Inc.

Forward Citations = 2,574

350 inventors:

goldMedal James F Blake (106 out of 113 patents)

silverMedal Eli M Wallace (79 out of 91 patents)

bronzeMedal Joseph P Lyssikatos (66 out of 141 patents)

4.  Yutong Jiang (64 out of 68 patents)

5.  Steven Wade Andrews (64 out of 98 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Array Biopharma Inc.. Retrieved from https://idiyas.com/company/array-biopharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…